Core Viewpoint - Tianyan Pharmaceuticals (ADAG) experienced a significant stock price increase of 11.73%, reaching $2.19 per share, with a total market capitalization of $103 million as of August 20 [1] Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1] - The company recorded a net loss attributable to shareholders of $33.42 million, reflecting a year-over-year decline of 76.41% [1] Company Overview - Tianyan Pharmaceuticals is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker ADAG, focused on discovering and developing novel cancer immunotherapies based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to develop new antibodies with high safety and efficacy, aiming to benefit more cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is driving the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) has experienced a significant stock price increase of 7.14%, reaching $2.1 per share, with a total market capitalization of approximately $98.98 million as of August 20 [1] Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, reflecting a year-on-year decrease of 99.43% [1] - The company's net profit attributable to shareholders was -$33.42 million, representing a year-on-year decline of 76.41% [1] Company Overview - Tianyan Pharmaceuticals is a biopharmaceutical company focused on the development of clinical products driven by its proprietary platform, aiming to discover and develop novel cancer immunotherapies based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to create new antibodies with high safety and efficacy, benefiting cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) is a biopharmaceutical company focused on developing innovative cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net profit attributable to shareholders of -$33,424,100, reflecting a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a platform-driven biopharmaceutical company in the clinical product development stage, dedicated to discovering and developing new cancer immunotherapies [1]. - The company’s antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, aiming to create potentially innovative or best-in-class products globally [1].

Core Viewpoint - Tianyan Pharmaceutical (ADAG) is a biopharmaceutical company focused on developing innovative cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceutical reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net profit attributable to shareholders of -$33,424,100, reflecting a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceutical is a platform-driven company engaged in the clinical product development phase, dedicated to discovering and developing new cancer immunotherapies [1]. - The company’s antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, aiming to create potentially innovative or best-in-class products globally [1].

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) is a biopharmaceutical company focused on developing innovative cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net profit attributable to shareholders of -$33,424,100, reflecting a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a platform-driven biopharmaceutical company in the clinical product development stage, dedicated to discovering and developing new cancer immunotherapies [1]. - The company’s antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, aiming to create potentially innovative or best-in-class products globally [1].

财务数据显示，截至2024年12月31日，天演药业收入总额10.32万美元，同比减少99.43%；归母净利 润-3342.41万美元，同比减少76.41%。 资料显示，天演药业公司(纳斯达克股票代码:ADAG)是平台驱动并拥有自主平台产出的临床产品开发阶 段的生物制药公司,公司致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。借助计算生物学和 人工智能相结合的强大平台,公司研制出高安全性和有效性的新型抗体,为更多癌症患者带来了福音。公 司的抗体发现引擎——"动态精准抗体库"(Dynamic Precision Library),正在推动天演药业的产品管线开发, 致力于打造潜在的全球创新或同类最佳型产品。 本文源自：金融界 8月14日，天演药业(ADAG)盘中上涨20.61%，截至21:52，报1.99美元/股，成交9516.0美元，总市值 9379.12万美元。 作者：行情君 ...

本文源自：金融界 作者：行情君 财务数据显示，截至2024年12月31日，天演药业收入总额10.32万美元，同比减少99.43%；归母净利 润-3342.41万美元，同比减少76.41%。 资料显示，天演药业公司(纳斯达克股票代码:ADAG)是平台驱动并拥有自主平台产出的临床产品开发阶 段的生物制药公司,公司致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。借助计算生物学和 人工智能相结合的强大平台,公司研制出高安全性和有效性的新型抗体,为更多癌症患者带来了福音。公 司的抗体发现引擎——"动态精准抗体库"(Dynamic Precision Library),正在推动天演药业的产品管线开发, 致力于打造潜在的全球创新或同类最佳型产品。 8月13日，天演药业(ADAG)盘中上涨10.47%，截至21:51，报2.11美元/股，成交1.46万美元，总市值 9944.70万美元。 ...

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) is a biopharmaceutical company focused on developing innovative cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net profit attributable to shareholders of -$33,424,100, reflecting a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a platform-driven biopharmaceutical company in the clinical product development stage, dedicated to discovering and developing new cancer immunotherapies [1]. - The company’s antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, aiming to create potentially innovative or best-in-class products globally [1].

Group 1 - The top five Chinese concept stocks that experienced the largest declines in closing prices are Mint, e家快服, 健永生技, AirNet Technology, and 天演药业, with declines of 33.18%, 21.15%, 18.46%, 17.77%, and 16.59% respectively [1] - Mint's latest price is 5.660, with a drop of 2.810 and a trading volume of 17.6069 million [1] - e家快服's latest price is 1.100, with a decrease of 0.295 and a trading volume of 514.7 thousand [1] - 健永生技's latest price is 40.410, with a decline of 9.150 and a trading volume of 13.7547 million [1] - AirNet Technology's latest price is 2.800, with a drop of 0.605 and a trading volume of 196.45 thousand [1] - 天演药业's latest price is 1.910, with a decrease of 0.380 and a trading volume of 33.98 thousand [1]

Table of Contents Exhibit 99.2 ADAGENE INC. INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | Unaudited Interim Condensed Consolidated Financial Statements | PAGES | | --- | --- | | Unaudited Interim Condensed Consolidated Balance Sheets as of December 31, 2024 and June 30, 2025 | F-2 | | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended | | | June 30, 2024 and 2025 | F-3 | | Unaudited Interim Condensed Consolidated Statements of Ch ...